Logo image of ALZN

ALZAMEND NEURO INC (ALZN) Stock Price, Quote, News and Overview

NASDAQ:ALZN - Nasdaq - US02262M5067 - Common Stock - Currency: USD

4.18  -0.97 (-18.83%)

Premarket: 4 -0.18 (-4.31%)

ALZN Quote, Performance and Key Statistics

ALZAMEND NEURO INC

NASDAQ:ALZN (5/13/2025, 8:16:17 PM)

Premarket: 4 -0.18 (-4.31%)

4.18

-0.97 (-18.83%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High135.54
52 Week Low3.94
Market Cap27.63M
Shares6.61M
Float6.38M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-28 2025-07-28/bmo
IPO06-15 2021-06-15


ALZN short term performance overview.The bars show the price performance of ALZN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ALZN long term performance overview.The bars show the price performance of ALZN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALZN is 4.18 USD. In the past month the price decreased by -41.14%. In the past year, price decreased by -92.67%.

ALZAMEND NEURO INC / ALZN Daily stock chart

ALZN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.31 332.57B
AMGN AMGEN INC 13.03 145.41B
GILD GILEAD SCIENCES INC 13.1 126.28B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.06B
REGN REGENERON PHARMACEUTICALS 12.96 61.99B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.71B
ARGX ARGENX SE - ADR 92.41 33.12B
ONC BEIGENE LTD-ADR 5.58 24.22B
BNTX BIONTECH SE-ADR N/A 22.72B
NTRA NATERA INC N/A 20.70B
SMMT SUMMIT THERAPEUTICS INC N/A 18.28B
BIIB BIOGEN INC 7.79 18.05B

About ALZN

Company Profile

ALZN logo image Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Company Info

ALZAMEND NEURO INC

3480 Peachtree Road NE,, Second Floor, Suite 103

Atlanta GEORGIA US

CEO: Stephan Jackman

Employees: 4

ALZN Company Website

ALZN Investor Relations

Phone: 18447226333

ALZAMEND NEURO INC / ALZN FAQ

What is the stock price of ALZAMEND NEURO INC today?

The current stock price of ALZN is 4.18 USD. The price decreased by -18.83% in the last trading session.


What is the ticker symbol for ALZAMEND NEURO INC stock?

The exchange symbol of ALZAMEND NEURO INC is ALZN and it is listed on the Nasdaq exchange.


On which exchange is ALZN stock listed?

ALZN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALZAMEND NEURO INC stock?

8 analysts have analysed ALZN and the average price target is 20.4 USD. This implies a price increase of 388.04% is expected in the next year compared to the current price of 4.18. Check the ALZAMEND NEURO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALZAMEND NEURO INC worth?

ALZAMEND NEURO INC (ALZN) has a market capitalization of 27.63M USD. This makes ALZN a Nano Cap stock.


How many employees does ALZAMEND NEURO INC have?

ALZAMEND NEURO INC (ALZN) currently has 4 employees.


What are the support and resistance levels for ALZAMEND NEURO INC (ALZN) stock?

ALZAMEND NEURO INC (ALZN) has a resistance level at 8.2. Check the full technical report for a detailed analysis of ALZN support and resistance levels.


Should I buy ALZAMEND NEURO INC (ALZN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALZAMEND NEURO INC (ALZN) stock pay dividends?

ALZN does not pay a dividend.


When does ALZAMEND NEURO INC (ALZN) report earnings?

ALZAMEND NEURO INC (ALZN) will report earnings on 2025-07-28, before the market open.


What is the Price/Earnings (PE) ratio of ALZAMEND NEURO INC (ALZN)?

ALZAMEND NEURO INC (ALZN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.17).


ALZN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALZN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALZN. While ALZN has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALZN Financial Highlights

Over the last trailing twelve months ALZN reported a non-GAAP Earnings per Share(EPS) of -15.17. The EPS increased by 18.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -102.51%
ROE -124.08%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%95%
Sales Q2Q%N/A
EPS 1Y (TTM)18.88%
Revenue 1Y (TTM)N/A

ALZN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to ALZN. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners2.09%
Ins Owners3.75%
Short Float %N/A
Short Ratio0.98
Analysts
Analysts80
Price Target20.4 (388.04%)
EPS Next Y94.04%
Revenue Next YearN/A